COVID‐19 outbreak: An experience to reappraise the role of hospital at home in the anti‐cancer drug injection

Mittaine‐Marzac, Bénédicte; Zogo, Arsene; Crusson, Jean‐Christophe; Cheneau, Valerie; Pinel, Marie‐Claire; Brandely‐Piat, Marie‐Laure; Amrani, Fatma; Havard, Laurent; Balladur, Elisabeth; Louissaint, Taina; Nivet, Laurence; Ankri, Joel; Aegerter, Philippe; De Stampa, Matthieu

BACKGROUND: The COVID‐19 outbreak has posed considerable challenges to the health care system worldwide, especially for cancer treatment. We described the activity and the care organisation of the Hospitalisation At Home (HAH) structure during the pandemic for treating patients with anti‐cancer injections. METHODS: We report the established organisation, the eligibility criteria, the patient characteristics, the treatment schemes and the stakeholders’ role during two 5‐week periods in 2020, before and during the French population's lockdown. RESULTS: The increase of activity during the lockdown (+32% of treated patients, +156% of new patients and +28% of delivered preparations) concerned solid tumour, mainly breast cancer, even if haematological malignancies remained the most frequent. Thirty different drugs were delivered, including three new drugs administered in HAH versus 19 during the routine period (p < 0.01). For those clinical departments accustomed to using HAH, the usual organisation was kept, but with adjustments. Five clinical departments increased the number of patients treated at home and widened the panel of drugs prescribed. Three oncology departments and one radiotherapy department for the first time solicited HAH for anti‐cancer injections, mainly for immunotherapy. We adjusted the HAH organisation with additional human resources and allowed to prescribe drugs with an infusion time of <30 min only for the new prescribers. CONCLUSION: HAH allowed for the continuation of anti‐cancer injections without postponement during the pandemic, and for a decrease in unnecessary patient travel to hospital with its concomitant COVID‐19 transmission risk. Often left out of guidelines, the place of HAH in treating cancer patients should be reappraised, even more so during a pandemic.